Human Angiostatin K1-3 ELISA Kit | PLG elisa kit

Human Angiostatin K1-3 PicoKine ELISA Kit

Cat. Num. AAA175925

• Reactivity: Human
• Synonyms: Angiostatin K1-3; Human Angiostatin K1-3 PicoKine ELISA Kit; Plasminogen; plasminogen; Ang K1-3; PLG elisa kit

• Reactivity: Human
• Specificity: Natural and recombinant human Angiostatin K1-3
• Sequence Length: 810

• Samples: Serum, plasma and cell culture supernates
• Assay Type: Sandwich
• Detection Range: 156pg/ml-10,000pg/ml
• Sensitivity: < 50pg/ml
• Intra-assay Precision: Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
• Inter-assay Precision: Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
• Preparation and Storage: Store at 4 degree C for 6 months, at -20 degree C for 12 months. Avoid multiple freeze-thaw cycles (Shipped with wet ice.)

Typical Testing Data/Standard Curve (for reference only)

(Human Angiostatin K1-3 PicoKine ELISA Kit standard curve )

Related Product Information for PLG elisa kit

Principle of the assay: human Angiostatin K1-3 ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for Angiostatin K1-3 has been precoated onto 96-well plates. Standards and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for Angiostatin K1-3 is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the human Angiostatin K1-3 amount of sample captured in plate.
Background: Ang K1-3 is a single, non-glycosylated polypeptide chain containing 259 amino acids. It represents a proteolytic fragment of plasminogen containing the first three kringle structures. Ang K1-3 reduces endothelial cell proliferation and acts as a potent inhibitor of angiogenesis and tumor growth. It displays increased inhibitory activity (ED50 =70 nM) relative to kringles 1-4 (ED50 = 135 nM).

NCBI and Uniprot Product Information

• NCBI GI #: 130316
• NCBI GeneID: 5340
• UniProt Accession #: P00747; Q15146; Q5TEH4; Q6PA00
• Molecular Weight: 90,569 Da
• NCBI Official Full Name: Plasminogen
• NCBI Official Synonym Full Names: plasminogen
• NCBI Official Symbol: PLG
• NCBI Protein Information: plasminogen
• UniProt Protein Name: Plasminogen
• Protein Family: Plasminogen
• UniProt Gene Name: PLG
• UniProt Entry Name: PLMN_HUMAN

NCBI Description

The protein encoded by this gene is a secreted blood zymogen that is activated by proteolysis and converted to plasmin and angiostatin. Plasmin dissolves fibrin in blood clots and is an important protease in many other cellular processes while angiostatin inhibits angiogenesis. Defects in this gene are likely a cause of thrombophilia and ligneous conjunctivitis. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Dec 2009]

Uniprot Description

Plasminogen: Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Defects in PLG are the cause of plasminogen deficiency (PLGD). PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa. Belongs to the peptidase S1 family. Plasminogen subfamily.

Protein type: Motility/polarity/chemotaxis; Secreted, signal peptide; Protease; EC 3.4.21.7; Secreted

Chromosomal Location of Human Ortholog: 6q26

Cellular Component: extracellular space; extrinsic to external side of plasma membrane; cell surface; plasma membrane; extracellular region

Molecular Function: protein domain specific binding; protein binding; serine-type peptidase activity; serine-type endopeptidase activity; apolipoprotein binding; receptor binding

Biological Process: platelet activation; extracellular matrix organization and biogenesis; tissue remodeling; myoblast differentiation; muscle maintenance; extracellular matrix disassembly; negative regulation of cell proliferation; fibrinolysis; negative regulation of fibrinolysis; platelet degranulation; cellular protein metabolic process; proteolysis involved in cellular protein catabolic process; tissue regeneration; positive regulation of fibrinolysis; blood coagulation; transmembrane transport

Disease: Plasminogen Deficiency, Type I